Pharmsynthez (MOEX:LIFE)
Russia · Delayed Price · Currency is RUB 4.505
+0.415 (10.15%)
At close: Jul 8, 2022
Pharmsynthez Income Statement
Financials in millions RUB. Fiscal year is January - December.
Millions RUB. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 154 | 155.92 | 247.35 | 379.67 | 438.33 | 371.66 | |
Revenue Growth (YoY) | -33.42% | -36.96% | -34.85% | -13.38% | 17.94% | 27.68% |
Cost of Revenue | 109.26 | 116.51 | 242.38 | 295.21 | 280.94 | 211.74 |
Gross Profit | 44.74 | 39.41 | 4.97 | 84.46 | 157.39 | 159.92 |
Selling, General & Admin | 131.63 | 116.62 | 155.79 | 194.74 | 260.94 | 256.96 |
Research & Development | - | - | - | 16.8 | 54.18 | 46.02 |
Other Operating Expenses | 74.66 | 93.59 | 152.68 | -1.68 | -90.31 | -12.28 |
Operating Expenses | 206.29 | 210.21 | 308.47 | 210.42 | 384.94 | 307.28 |
Operating Income | -161.55 | -170.8 | -303.5 | -125.96 | -227.55 | -147.36 |
Interest Expense | -27.59 | -28.33 | -31.03 | -41.33 | -36.38 | -29.55 |
Interest & Investment Income | 0.19 | 0.25 | 0.95 | 0.1 | 3.04 | 2.26 |
Earnings From Equity Investments | - | - | - | -14.38 | -17.04 | -56.2 |
Currency Exchange Gain (Loss) | -7.86 | -7.86 | -35.67 | -8.58 | 18.69 | -104.71 |
Other Non Operating Income (Expenses) | 25.14 | 13.26 | 72.15 | -0.01 | -56.43 | -0.05 |
EBT Excluding Unusual Items | -171.68 | -193.49 | -297.09 | -190.15 | -315.66 | -335.61 |
Gain (Loss) on Sale of Investments | - | - | 3.76 | -19.49 | -388.56 | -196.11 |
Gain (Loss) on Sale of Assets | -9.9 | -9.9 | - | 0.92 | -29.18 | 4.51 |
Other Unusual Items | -5.41 | -5.41 | 303.53 | - | - | - |
Pretax Income | -186.99 | -208.8 | 10.19 | -208.72 | -733.4 | -527.21 |
Income Tax Expense | 28.71 | 45.12 | -244.22 | -1.22 | -35.85 | -2.4 |
Earnings From Continuing Operations | -215.7 | -253.91 | 254.41 | -207.49 | -697.55 | -524.81 |
Net Income | -215.7 | -253.91 | 254.41 | -207.49 | -697.55 | -524.81 |
Preferred Dividends & Other Adjustments | -0 | -0 | - | - | - | - |
Net Income to Common | -215.7 | -253.91 | 254.41 | -207.49 | -697.55 | -524.81 |
Shares Outstanding (Basic) | 444 | 440 | 440 | 301 | 301 | 301 |
Shares Outstanding (Diluted) | 444 | 440 | 440 | 301 | 301 | 301 |
Shares Change (YoY) | 1.23% | - | 46.30% | - | - | - |
EPS (Basic) | -0.49 | -0.58 | 0.58 | -0.69 | -2.32 | -1.74 |
EPS (Diluted) | -0.49 | -0.58 | 0.58 | -0.69 | -2.32 | -1.74 |
Free Cash Flow | - | - | - | -6.82 | -62.97 | -242.45 |
Free Cash Flow Per Share | - | - | - | -0.02 | -0.21 | -0.81 |
Gross Margin | 29.05% | 25.27% | 2.01% | 22.24% | 35.91% | 43.03% |
Operating Margin | -104.91% | -109.54% | -122.70% | -33.18% | -51.91% | -39.65% |
Profit Margin | -140.06% | -162.85% | 102.85% | -54.65% | -159.14% | -141.21% |
Free Cash Flow Margin | - | - | - | -1.80% | -14.37% | -65.23% |
EBITDA | -132.97 | -142.07 | -264.98 | -106.06 | -196.35 | -102.96 |
EBITDA Margin | -86.34% | -91.11% | -107.13% | -27.94% | -44.80% | -27.70% |
D&A For EBITDA | 28.58 | 28.74 | 38.52 | 19.9 | 31.2 | 44.4 |
EBIT | -161.55 | -170.8 | -303.5 | -125.96 | -227.55 | -147.36 |
EBIT Margin | -104.91% | -109.54% | -122.70% | -33.18% | -51.91% | -39.65% |
Advertising Expenses | - | 0.45 | - | 5.76 | 12.32 | 7.2 |